Therapeutic possibilities of 131I-MIBG in metastatic carcinoid tumors--preliminary report.
The poor results of traditional therapy in advanced carcinoid tumors and the well-proven uptake of 131I-MIBG shown by some of these tumors induced us to attempt a radiometabolic approach. We selected for the treatment 5 patients (3 men and 2 women) who showed progression of disease, a fairly good uptake of 131I-MIBG with severe related symptoms, and a poor response to traditional therapy. A cumulative radioactivity of 5.5-29.6 GBq was given. Acute side effects after 131I-MIBG administration or late radiation-induced damages were not observed. Symptoms increased during the first 2-4 weeks in 2 patients: in one of these relief was achieved with drugs. Results concerning objective remission of the disease were unsatisfactory. In contrast, definite improvement of symptoms was shown in 2 of 5 patients, resulting in a better quality of life.
Guerra
P
P
Servizio Medicina Nucleare, Spedali Civili, Brescia, Italy.
Colombo
L
L
Maira
G
G
Pagliaini
R
R
Terzi
A
A
Pizzocaro
C
C
Dottorini
M E
ME
Lomuscio
G
G
Bestagno
M
M
D019797:3-Iodobenzylguanidine; D000368:Aged; D002276:Carcinoid Tumor / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine